Collagen Peptide and Gelatin Market to Report a CAGR of 9.4% by 2025

Acquisitions, strategic collaboration, and diverse offerings are the major trends that are prevailing in the international market for collagen peptide and gelatin market. As the market is ancillary to various other industries like personal care, cosmetics, and pharmaceuticals, it displays a diverse and dynamic vendor landscape. Taking overall scenario into consideration, it witnesses high competition with many leading market players jostling with each other in terms of partnerships and innovations so as to achieve the topmost position, observes Transparency Market Research (TMR) in its latest market research study.

Read Report Overview: https://www.transparencymarketresearch.com/collagen-peptide.html

The prominent market players are making an effort with various market tactics and strategies so as to fortify their foothold in the international market for collagen peptide and gelatin. For example, various market players like Rousselot making participation in many of the international events so as to promote their product internationally. Similarly, Gelita AG, Catalent, Inc., and Nitta Gelatin, Inc. are looking at the expansion of their presence gelatininternationally through widening and diversification of their product portfolio and more funding in research & development and expansion of sales. Leading companies like Amicogen, Inc., on the other hand are taking advantage of biotechnology and other environment friendly methods to gain traction, mentions a research analyst.

Apart from assisting enterprises to obtain competitive edge, these market strategies have further positive influence on the overall operations of the market. In accordance with the market research report by TMR, the world market for collagen peptide and gelatin market is expected to display a growth rate of 9.4% CAGR between the time period that extends from the year 2016 and 2025. Expanding at this pace, the said market was valued at around US$ 11.15 bn by the end of the year 2025, from the earlier valuation of US$ 4.52 bn in the year 2016.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1070

Asia Pacific to Offer Promising Opportunities with the Expansion of Pharmaceutical Industry

The major geographical categories of the international market for collagen peptide and gelatin are Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific. The regions of North America and Europe have led the said market in the year 2015 amongst other prime geographical segments. Together those two geographies accounted for 60% of the total market share. Various factors are responsible for the growth of the said market. Factors such as the increased investment by many market players, support from the government, fast growth in technological advancement, and growing prevalence various diseases are forecasted to boost the said market in Europe and North America. The region of Asia Pacific, however, is foreseen to expand at a very high CAGR owing to the widespread prevalence of untapped opportunities and unmet medical needs across various emerging nations. Apart from this, the regional market is forecast to gain from the increasing investment by players, and augmented funding towards the improvement of healthcare infrastructure by various governments.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1070

Wide and Diverse Variety of Applications to Encourage Market Growth

In accordance with a market research study, the said market is primarily benefitting from the increasing sales of nutraceuticals on account of the soaring awareness about personal well-being amongst consumers across the globe. With consumers across the world becoming more and more worried about their lifestyle and health, the requirement for dietary supplements has bolstered as well. In addition to that, an increased number of consumers are witnessed going for nutraceuticals so as to avert lifestyle associated and age-related illnesses. Spurred by these above-mentioned factors, the world market for collagen peptide and gelatin is expected to experience an accelerated pace of market gains. Taking into consideration these growth-promoting factors, it is expected that the said market is expected to gain from the improvement of economic condition of consumers worldwide especially those who live in the emerging economies. The market if further estimated to benefit from increasing occurrences of obesity and expanding base of geriatric population.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Menopausal Hot Flashes Market to Surge at a CAGR of 3.70% by 2023

The global market for menopausal hot flashes is a moderately fragmented market, in which the top eight players collectively held a share of more than 50% in 2014, states a new research study by Transparency Market Research (TMR). Novartis AG and Pfizer Inc., the top two vendors, which accounted for nearly 30% of this market in 2014, are expected to maintain their stronghold over the next few years. Pfizer is expected to gain from its robust presence across North America while Novartis will benefit from its wide-ranging product portfolio for the treatment of menopausal hot flashes in the years to come, notes the study.

According to this report, the total opportunity in the global menopausal hot flashes market was US$3.77 bn in 2014. Researchers predict this market to rise at a CAGR of 3.70% during the period from 2015 to 2023 and increase to US$5.28 bn by the end of the forecast period.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2856

Demand for Hormonal Products to Remain Strong

According to the report, hormonal products have been witnessing an overwhelming demand across the world, as people prefer hormone replacement therapies for the treatment of menopausal hot flashes. In 2014, the hormonal products segment held a staggering 95% of the overall market and is anticipated to continue on the same track over the next few years. Non-hormonal products, however, are expected to gain momentum in the near future, since the awareness regarding the harmful effects hormonal therapies on women’s health is increasing considerably.

In terms of the geography, the global market for menopausal hot flashes is led by North America, reports the study. The increasing incidence of menopausal vasomotor symptoms in the female population in this region is the key factor behind the growth of this market in North America. In 2014, the regional market acquired a share of 66% in the overall market and is projected to remain on the top over the period of the forecast.

Read Report Overview: https://www.transparencymarketresearch.com/menopausal-hot-flashes.html

Amongst others, the menstrual hot flashes market in Asia Pacific is anticipated to outshine in terms of value and volume in the next few years due to the rising awareness pertaining to menopause-related health issues and the increasing disposable income of consumers in this region.

Swift Approval of New Treatments to Drive Growth

“The global market for menopausal hot flashes is gaining substantial impetus from the rising instances of night sweats caused by menopause and vasomotor symptoms, commonly known as, hot flashes,” says the author of this study. The increasing number of favorable initiatives commenced by several governments and private healthcare institutes to raise the awareness regarding women’s health among people across the world is another important factor that is boosting this market.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2856

Going forward, the speedy approval of new treatments is expected to create new streams for revenue generation for market players in the near future. However, the increasing availability of alternative therapies at a much cheaper rate may limit the growth of this market over the forecast period, states the resesrch report.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

High Potency Active Pharmaceutical Ingredient Market Will be Worth US$25.1 bn by 2023

Development of Targeted Therapeutic Drugs Drives Global HPAPI Market

The booming oncology research and rising cases of cancer, diabetes, and other cardiovascular diseases have created a sizeable demand for dedicated treatments, thereby driving the high potency active pharmaceutical ingredient (HPAPI) market. The HPAPI market stood at a valuation of US$2.64 bn in 2014. The cost containment strategies adopted by companies through outsourcing are favoring market growth. This has brought down the cost of drugs drastically, making them affordable to a larger audience. The positive result of this trend is seen on the increased focus of companies on drug development and commercialization. As a result of these favorable trends, the HPAPI market is projected to be worth US$25.11 bn by 2023. Between 2015 and 2023, the market is expected to expand at a CAGR of 8.3%.

Read Report Overview: http://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html

A promising pipeline of targeted therapeutic drugs will also help the market progress in the coming years. These drugs have minimal side effects and impact targeted areas, thereby helping the patient to recover faster with no lingering after effects. These positive perceptions surrounding HPAPIs combined with the near-expiration dates of blockbuster drugs, which will offer several generic drug manufacturers a chance to offer affordable drugs, will further the market’s growth. Consistent research and development to mimic branded drugs will create alternative and cost-effective treatments for patients across the globe, thereby augmenting the growth rate of the market.

Request Sample of Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=748

Emerging Nations in Asia Pacific Becoming Hubs of Generic Drug Manufacturing, to Aid HPAPI Market Growth

Asia Pacific is the expected to be the most lucrative market for high potency active pharmaceutical ingredients due to the soaring contract manufacturing activities in the region. Analysts predict that China will surpass Japan’s current share of 40% in the Asia Pacific market by the end of 2025. This change will be a result of low labor costs in China, well-equipped manufacturing plants, and supportive foreign exchange policies.

India will also be an upcoming high potency active pharmaceutical ingredients market due to the growing concentration of pharmaceutical manufacturing activities in the country. In the forecast period, the country is expected to be the hub for generic drug manufacturing. The growing investments by key players in India are also anticipated to boost this market in the near future. During the forecast period of 2015 to 2023, the Asia Pacific HPAPI market is expected to rise at a CAGR of 10.1%.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=748

Oncology Drugs Show Maximum Demand

The oncology drugs segment has been the leading segment of the global high potency active pharmaceutical ingredient market. This segment is expected to expand at CAGR of 8.3% during the forecast period. The introduction of innovative drugs is the primary growth driver for the oncology segment. Analysts predict that the patent expiry of blockbuster drugs such as Herceptin, Rituxan, and Humira will pave the way for generic drug manufacturers, thereby making these drugs affordable to a wide number of patients.

Some of the leading players operating in the global high potency active pharmaceutical ingredient market are WuXi AppTec, Sigma-Aldrich Co. LLC, Pfizer, Inc., Sandoz International GmbH, Novasep, Lonza Group, Dr. Reddy’s Laboratories, Cambrex Corporation, and Alkermes plc. The fragmented nature of this market will result in strategies to acquire and merge with regional players to gain the first-mover advantage.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=748

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Hospital Acquired Disease Testing Market Will be Worth US$2.07 bn by 2023

The global hospital acquired disease testing market is consolidated due to presence of very few number of players. However, these companies are engaged in high rivalry among themselves, exhibiting in the prevalence of a high degree of competition in the market. Transparency Market Research (TMR) in a report estimates that the scope for new players is very limited in the competitive landscape of this market. Some of the key players in this market include Thermo Fisher Scientific, Inc., Becton Dickinson and Company, Roche, Abbott Laboratories, and Alere, Inc. These companies are striving to capitalize on the emerging opportunities for expansion in the developing countries. These players are strengthening their position in the market while focusing on extensive research and development programs to build innovative hospital acquired disease testing products.

Read Report Overview: https://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html

Transparency Market Research has projected that the market value will reach US$2.07 bn by the end of 2023 from its valuation of US$416.7 mn in 2014. The market is anticipated to expand with a healthy CAGR of 19.9% for the forecast period 2015-2023.

In the year 2014, North America emerged as the leading regional market for hospital acquired disease testing, holding nearly 38.5% to the global market. Within the region, the U.S held dominance owing to the increasing number of people suffering from hospital acquired infections. In the same year, Europe contributed the second largest share in the global market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759

Increasing Awareness Regarding HAIs to Propel the Global Market

The increasing incidence of hospital acquired infections (HAI) is one of the key factors propelling the global hospital acquired disease testing market. For the prevention of these infections many countries such as the U.S. have issued rules and regulations to be mounted in the hospitals and clinics. For instance, the U.S. has regulated HHS Action Plan to reduce infections auqired in hospitals. These government plans and movements and increasing investments are expected to poise to growth of the global market of hospital acquired disease testing. Furthermore, the rising number of pathogens with drug-resistant abilities is foreseen to help the market expand. Numerous hospitals around the world are facilitating the pathogen detection procedures with improved surveillance culture. To prevent the transmission of diseases, various health organizations are demanding for effective hospital acquired disease testing solutions.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1759

Factors such as growing concerns about control and prevention of nosocomial infections, increasing number of diseases that increase risk of hospital associated infections, initiatives taken up by governments to manage nosocomial infections, and increasing geriatric population are some of the key factors aiding the market’s expansion. Furthermore, the developing health facilities of developing countries of Asia Pacific are most likely fuel the global hospital acquired disease testing market.

Poor Regulations of Less Developed Countries Could Hinder the Market Growth

The majority of regulations regarding molecular-biology-based diagnostics remain un-updated, which can act as a restraining factor. Furthermore, the absence of control authorities and efficient control programs in less developed countries could hinder the market growth. For instance, African countries such as Nigeria do not have any effective programs or authority to prevent or control hospital acquired diseases.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1759

Nevertheless, the rising health concerns among patients around the world are anticipated to help the market sustain its trajectory and grow over the forecast period. Furthermore, escalating number of urinary tract infection is anticipated fuel the demand for hospital acquires disease testing. Moreover, the increasing incidence of MRSA, pneumonia, and surgical site infection are expected to boost the market.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Oral Contraceptive Pills Market Will be Worth US$22.9 bn by 2023

According to TMR, the global oral contraceptive pills market is expected to be worth US$22.9 bn by 2023. On the basis of type, the position of combination oral contraceptive pill segment remains undisputed and is estimated to be worth US$18 bn by 2023. The segment is also identified as the fastest growing segment within the market. On the basis of category, the generic oral contraceptive pill segment will lead in the market. The segment will also witness highest growth rate in the forecast period, said a TMR analyst. On the basis of geography, North America shall continue to have a dominant hold over the market within the period from 2015 to 2023. However, Asia Pacific will expand at the fastest rate and emerge the most promising regional segment within the oral contraceptive pills market. High population and growing awareness among the people about the availability of oral contraceptive pills as an easy method to control birth will be key reasons behind the growth of this market.

Read Report Overview: https://www.transparencymarketresearch.com/oral-contraceptive-pills-market.html

Government Initiatives to Spread Awareness Programs Aids Growth

The growing incidence of unwanted pregnancies is becoming a key factor fueling the demand for oral contraceptive pills. It has been found that the oral contraceptive pills are most consumed by women falling under the age group of 15 and 44. As per the The Centers for Disease Control and Prevention (CDC), the U.S. alone accounted for 37% of the total unwanted pregnancies in North America between 2006 and 2010. “The staggering growth of unintended pregnancies, not just among unmarried women, but also among those married will is fueling the growth of the global oral contraceptive pills market,” said a TMR analyst.

It has been found in one of the studies by The United Nations, that there has been an increase in the number of married women using at least one method of contraception, boosting the growth prospects of this market. Some of the other factors propelling the demand for contraceptives include the growing awareness among women, increasing efforts taken by governments to spread the awareness of contraceptives, NGOs initiating awareness programs across nations, and increasing maternal age. Late pregnancies are also aiding the growth of this market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8323

Religious and Ethical Norms to Deter Market from Growing to its Fullest Potential

Across many countries in the Middle East, oral contraceptives are restricted by various ethical, social, and religious barriers. This will act as a impeding factor for the growth of the oral contraceptive pills market. Oral contraceptive pills are perceived as a means of abortion and thus their sales suffer in these areas. Strict legal frameworks and policies towards reproductive rights in many countries will also challenge the growth of this market.

Companies in the global oral contraceptive pills market are focusing on untapped markets with unmet needs and improving their hold in the market. A case in point would be Mankind Pharma. This Indian-based company has expanded its business by exporting oral contraceptive pills to countries such as Ethiopia, Kenya, Uganda, and Tanzania. Some of the other strategies adopted by players include, launching of new products and increased effort in research and development of efficient products that have minimal side effects.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8323

As per Transparency Market Research (TMR), Teva Pharmaceutical and Allergan (Actavis) plc. are the two leading companies within this market. Some of the other local players in the market include: Taj Pharma, Alkem, and Zydus Alidec. It has been observed that a majority of the players offer combination oral contraceptive pills owing to their efficiency, low cost, and being most popular among women for birth control.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Global Cardiac Pacemaker Market to rise US$12.8 bn up to 2023

The global cardiac pacemaker market is characterized by the presence of leading companies: Medtronic, St. Jude Medical, and Boston Scientific. These three companies accounted for a whopping 76.4% of the market in 2014, states a report by Transparency Market Research (TMR). The competition is high between these top players in the market. The shares accounted for, by regional players in the global cardiac pacemaker market is small. Leading player Medtronic has gained highest market shares on account of its diverse product range in cardiac pacemakers. The company is well established and enjoys a very prominence in the market. St. Jude Medical on the other hand, has gained market shares on account of its consistent efforts to market and distribute products in developing nations. The company is investing in marketing its products in developing nations where the medical needs are unmet and is benefitting from this strategy.

Read Report Overview: https://www.transparencymarketresearch.com/cardiac-pacemakers-market.html

According to TMR, the global cardiac pacemakers market will be worth US$12.8 bn by 2023 and on the basis of volume the count is expected to exceed 2.4 mn by 2023. On the basis of product type, the implantable cardiac pacemakers have been popular and are slated to continue to remain so through 2023. In fact it is the segment which will witness the fastest growth during the forecast period. On the basis of technology, the dual chamber technology not only led in the past but will also lead in the years to come. The dual chamber technology segment will expand at the fastest CAGR in the forecast period.

Europe to Consume Highest Number of Cardiac Pacemakers

On the basis of geography, Europe led in the past and shall continue to do so for the rest of the forecast period, in terms of being the region consuming the most cardiac pacemakers. Europe is slated to account for 51.1% of the market by 2023, driven by growing number of patients suffering from heart diseases. North America however leads on the basis of revenue in the cardiac pacemaker market. Asia Pacific on the other hand will witness remarkable growth and emerge as the region displaying fastest growth rate. The region is anticipated to hold a 20.3% share of the cardiac pacemaker market by 2023. The market is driven by growing awareness about advanced pacemakers among the people in this region.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=393

Increasing Prevalence of Heart Diseases to Remain Key Factor Spurring Demand for Cardiac Pacemakers

According to an expert TMR analyst, the growing demand for cardiac pacemakers is because of the increasing geriatric population and a large number of people suffering from various heart issues. There has been a steady rise in the number of people who are genetically prone to heart diseases. In addition to this, detrimental lifestyle is also increasing the number of people suffering from heart diseases, boosting the demand for cardiac pacemakers. The developed nations such as the U.S. and those in the European region have an increasing number of patient suffering heart failure. These nations also have a high geriatric population base and thus, both these regions are fueling the growth of the global cardiac pacemakers market.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=393

Players Cutting Down on Profits due to The Affordable Healthcare Act

In order to make healthcare affordable, The Affordable Healthcare Act was implemented in the U.S. This led to a 2.5% excise duty being imposed on all medical devices, including cardiac pacemakers. Since the U.S. is one of the key consumers of cardiac pacemakers, players in the market in the region have had to reduce their profit so as to cut down the overall cost of cardiac pacemakers. This cut down on profit has become essential for keeping up with the hugh demand for cardiac pacemakers. Another factor challenging the growth of this market is the classification of cardiac pacemakers as Class III high-risk medical devices, by the U.S. FDA. This requires all cardiac pacemakers to be tested for safety even before getting an approval. This in turn leads to further increase in cost as well as delays the arrival of cardiac pacemaker in the market.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Pain Management Devices Market Size to Accelerate at a Rapid CAGR of 7.6% by 2023

Global Pain Management Devices Market: Snapshot

Patients suffering from chronic medical conditions such as cancer, diabetes, and obesity are highly susceptible to chronic pains and therefore, their increasing prevalence is providing tremendous momentum to the global pain management devices market. According to various scientific articles published in BioMed Central, over 20% of the adult global population suffers from chronic pain and 10% population are newly diagnosed with chronic pain each year. Changing demographics and widening pool of global geriatric population are bringing a large chunk of population under the chronic illness category. This is, thereby, augmenting the global market.

Read Report Overview: https://www.transparencymarketresearch.com/pain-management-drugs-devices.html

Moreover, the commercialization of advanced and innovative therapeutic products and the availability of favorable reimbursement policies are creating a staggering volume of global demand for pain management devices. However, the side effects such as surgical infection and skin erosion associated with neurostimulation implants are keeping the market from realizing its utmost potential. With all these factors put together, the global pain management devices market is estimated to reach a valuation of US$6.28 bn by 2023 from US$3.75 bn in 2016, progressing at a 7.6% CAGR between 2015 and 2023.

Neurostimulation Devices to Remain Most Valuable Product Segment through 2023

On the basis of product, the neurostimulation devices segment will continue to represent the lion’s share in the market. The rising incidence of chronic pain such as musculoskeletal and cancer pain and the commercialization of breakthrough technologies in the field of neurostimulation are driving the growth of the segment. A growing number of people with chronic pain in lower back, limbs, and legs are undergoing implantation of deep brain and spinal cord stimulation devices, which is leading to the greater uptake of effective neurostimulation devices worldwide. The high cost of these devices makes them the leading revenue contributor to the market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1143

The analgesic infusion pumps segment, on the other hand, is poised to post a remarkable CAGR of 10.3% during the forecast period. The high effectiveness, less pain, and superior safety features of the product are making them a preferred choice for pain management.

Growing Incidence of Lifestyle-related Diseases and Sports-related Injuries Fuels North America’s Dominance

North America will continue to be the leading revenue contributor to the global market, accounting for 48.7% of the overall market. The rising prevalence of lifestyle-related diseases and the growing incidence of sports-related injuries are boosting the demand for pain management devices in the region. Moreover, the growth of the region can be attributed to the birthing of innovative technologies and the presence of advanced healthcare facilities along with the improving access to it. The rapidly growing geriatric population can also be held responsible for the dominance of the region.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1143

In 2016, Europe was the second leading region. The burgeoning demand for technologically advanced products and increasing adoption of non-invasive and self-administered products are fuelling the growth of the region. However, by the end of the review period, the region is expected to lose its position to Asia Pacific.

Asia Pacific will rise at a CAGR higher than any other region during the same period. The growing incidence of neck and back pain among the populace and increasing cases of diabetes and chronic wounds are propelling the growth of the region. The widening base of geriatric population, particularly in Japan and China, is also playing a vital role in the increased sales of pain management devices in the region.

Some of the key players operating in the global pain management devices market are Boston Scientific Corp., St. Jude Medical, Bio-Medical Research (BMR) Ltd., Medtronic Plc, Smiths Medical, Baxter International Inc., Hospira Inc., Halyard Health, and Stryker Corp.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1143

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Biotherapeutics Cell Line Development Market Estimated to Accumulate more than US$100 mn by 2022

According to TMR, the global market for biotherapeutics cell line development market will be worth US$99.8 mn by 2022. On the basis of geography, North America has been leading in the market from many years. The North American market for biotherapeutics cell line development is predicted to be worth US$41 mn by 2022. Asia Pacific on the other hand is estimated to expand at the fastest pace in the coming years. By process, the single cell cloning segment will continue to enjoy leading status throughout the forecast period. On the basis of cell line development option, the outsourcing segment will emerge victorious for biotherapeutics, stated a TMR analyst.

Read Report Overview: https://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html

Growing Geriatric Population to Continue to Drive Market

The growing incidences of chronic diseases and increasing population of aged people are two important factors fueling the growth of the global biotherapeutics cell line development market. The growing geriatric population has led to an increase in the number of cases for degenerative, chronic, and autoimmune diseases. This in turn is favoring the demand for biotherapeutics cell line development. Some of the most prevalent diseases today that are boosting the growth of this market include: cancer, diabetes, and multiple sclerosis. The efficiency offered by biotherapeutics is gaining traction from patients as well as those within the medical line, for use in the treatment of the aforementioned diseases. This in turn is aiding the growth of the market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

New Players Face Entry Barriers on Account of Strict Regulations

“The stringent policies and regulations regarding the cell culture procedures is anticipated to be a key challenge for the growth of the global biotherapeutics cell line development market,” a TMR analyst said. These policies regulate the production of biotherapeutics and could crush the growth opportunities for several market players. The development of stable cell line producing biologics requires compliance with standard operating procedures. Monitoring of product quality through tests in line with regulations and SOPs is delaying product development and affecting market players. Moreover, such strict regulations act as entry barriers for new players.

On a positive notion however, the unmet medical needs of the patient population in developing economies of Asia Pacific, Latin America, and Africa will ensure a healthy growth of the biotherapeutics cell line development market. The increasing demand for antibodies will also lead to development and progress of the global biotherapeutics cell line development market.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8272

The global biotherapeutics cell line development market is highly consolidated and is led by Becton Dickinson and Co. and Beckman Coulter, which are the two leading companies within this market. These two companies collectively accounted for a whopping 85% of the total market in 2015, states Transparency Market Research (TMR) in its latest report. There lies a meager chance for new entrants to enter in the market on account of the high shares held by these two companies. It has also led to a reduced market shares for other companies. Some of the other companies in the global biotherapeutics cell line development market include: Catalent Inc., CMC Biologics, Lonza Group Ltd., Partec, Sony Biotechnology Inc., SAFC, Selexis SA, Boehringer Ingelheim Pharma GmbH & Co KG., ProBioGen AG, and Thermo Fisher Scientific Inc. The possibility of business expansion and growth opportunities lies mostly with the established companies. In the years to come, companies will need to focus on advancements and adoption of latest technology so as to gain a competitive edge above each other.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=8272

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Revenue in Disposable Syringes Market to Breach US$9.3 bn Mark by 2023

Global Disposable Syringes Market: Snapshot

The rapid increase in the number of injectable drugs to be approved recently has been a key contributor to the growth in demand for disposable syringes specifically, over other types of syringes. This is due to the growing number of patients afflicted with accidental needlestick injuries. Both factors thus work in tandem to create a staggering demand for disposable syringes and will continue to do so in the long term.

The number of disposable syringes being used has also increased due to the growth in point-of-care administration systems. These systems promote the self-administration of drugs, which can be easily done with modern disposable syringes with improved safety features.

Read Report Overview: https://www.transparencymarketresearch.com/disposable-syringes-market.html

The effective result of the above factors of influence on the market – along with a few others – for disposable syringes is expected to translate to a CAGR of 5.6% from 2015 to 2023. This market is expected to be valued above US$9.3 bn by the end of 2023 and close to US$6.5 bn by the end of 2016.

North America Remains Leading Disposable Syringe Consumer While Players Look to APAC for Bigger Opportunities

By the end of 2016, North America disposable syringe makers are expected to gain a revenue of US$3.9 bn, which is close to half of the total revenue earned on a global level. North America is expected to maintain its dominance over disposable syringes revenue till 2023, although it is expected to lose some percentage to the burgeoning Asia Pacific market. Europe will remain the second-largest region for disposable syringes till 2023. Both North America and Europe are showing a high demand for disposable syringes due to the growing number of injectable drugs in the market, improvements in syringe quality and safety through regulatory adherence, and the concern over a growing number of needlestick injuries.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1259

China and India are expected to be the two key lucrative avenues for disposable syringes players in the near future, owing to their high population densities and growth in healthcare expenditures. A large part of this growth in demand for disposable syringes is attributed to the increasing number of government and private initiatives for conducting immunization drives across the countries. Additionally, the higher interest shown by North American and European players in these regions is expected to add to the quality of disposable syringes available in the market, further increasing their consumption rates.

Safety Syringes to Gain Larger Share

Conventional disposable syringes have held the larger share by volume till now, and will be expected to hold the dominant share for a few more years. However, the segment is expected to lose its leading position to safety syringes which are gaining popularity at a rapid pace. Safety syringes already lead the market in terms of value. By 2023, safety syringes are expected to hold a revenue share of 84%.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1259

Key reasons for the high accelerated growth rate shown by safety syringes is the absence of any safety mechanisms in conventional ones. Safety syringes help protect patients from needlestick injuries and are just as accurate and easy to use as conventional disposable syringes.

The top manufacturers of disposable syringes in the world today include Becton, Dickinson & Company, B. Braun Melsungen AG, Medtronic plc, Terumo Corporation, Smiths Medical, and Retractable Technologies, Inc.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Geriatric Medicines Market Opportunity will Rise to US$ 948 bn by 2023

The global market for geriatric medicines stood at US$ 504.7 bn in 2014 and is projected to expand at a CAGR of 7.3 % during 2015–2023. Rising at this pace, the opportunities in the market is anticipated to reach US$ 948.0 bn by the end of 2023.

Asia Pacific to Provide Lucrative Growth Avenues in Coming Years

Regionally, the global geriatric medicines market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, the Asia Pacific market is expected to rise at the substantial CAGR over the forecast period. The growth of the regional market is expected to be fueled by the increasing prevalence of medical conditions and diseases affecting the aged people and substantial government initiatives in providing quality geriatric care through care units.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2445

Based on the disease condition, the geriatric medicines market is segmented into arthritis, cardiovascular, neurological, osteoporosis, respiratory, and cancer. Among these, the cardiovascular segment held the major revenue share in 2014 and is projected to rise at the fastest CAGR over the forecast period. The dominance of the segment is attributed to the rising prominence of cardiovascular conditions affecting the elderly people needing geriatric care and the mounting concerns related to cardiac attacks.

Governments’ Push for Quality Geriatric Care Bodes Well for Market

The global geriatric medicines market is primarily driven the general rise in the elderly populations in various regions, particularly in developing and developed nations. The growing prevalence of adults aged over 65 years that are affected by a variety of chronic conditions and the rising incidence of diseases such as neurological disorders, cancer, rheumatoid arthritis, and cardiovascular disorder are the key factors boosting the geriatric medicines market. A large number of aged people reliant on polypharmacy are prone to the side-effects due to the interactions of the different medications. This has propelled the demand for geriatric care, thereby catalyzing the geriatric medicines market.

Read Report Overview: https://www.transparencymarketresearch.com/geriatric-medicine-market.html

The increasing prevalence medication-related problems among older adults and the pressing need for palliative care are the seminal factors boosting the geriatric market. Furthermore, in recent years, the concerted efforts by governments in providing quality geriatric care in a number of emerging countries and the significant investments made by them in opening geriatric care units have accentuated the market. The rising prevalence of aged people suffering from different chronic conditions has fueled the demand for analgesics among the elderly population, thereby stimulating the uptake of geriatric medicines. The increasing prevalence of various cardiovascular conditions has triggered the incidence of heart attacks, thereby fueling the demand for geriatric medicines.

However, the lack of awareness about the availability of geriatric care among elderly patients in emerging nations is a crucial factor likely to impede the market to an extent. On the other hand, constant advances in healthcare infrastructure in several nations in developing and developed regions is expected to open up exciting opportunities for market players.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2445

Some of the prominent players operating in the global geriatric medicines market are Sanofi S.A., Pfizer, Inc., Novartis International AG, Merck & Company Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Ko. KG, Abbott Laboratories, Inc., and AstraZeneca plc. Several players are capitalizing on emerging opportunities in a number of developing nations as the governments are making substantial investments in providing geriatric medicine and palliative care, observes Transparency Market Research (TMR).

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/